UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors

British journal of cancer, 2015-03, Vol.112 (6), p.1011-1016

2015

Volltextzugriff (PDF)

Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling

Oncogene, 2016-04, Vol.35 (17), p.2166-2177

2016

Volltextzugriff (PDF)

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report

European journal of cancer (1990), 2003, Vol.39 (1), p.70-77

2003

Volltextzugriff (PDF)

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

British journal of cancer, 2004-03, Vol.90 (5), p.985-990

2004

Volltextzugriff (PDF)

Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma

European journal of cancer (1990), 2003-05, Vol.39 (8), p.1115-1120

2003

Volltextzugriff (PDF)

A medical cause for fifty shades of grey

Netherlands journal of medicine, 2016-08, Vol.74 (7), p.320-320

2016

Volltextzugriff (PDF)

258 Macrocytosis as a potential parameter associated with outcome in the treatment with tyrosine kinase inhibitors

European journal of cancer (1990), 2015-09, Vol.51, p.S45-S46

2015

Volltextzugriff (PDF)

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

British journal of cancer, 1998-11, Vol.78 (10), p.1342-1345

1998

Volltextzugriff (PDF)

Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: A corollary study to EORTC trial 18952

European journal of cancer (1990), 2011-02, Vol.47 (3), p.361-368

2011

Volltextzugriff (PDF)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

British journal of cancer, 2002-01, Vol.86 (1), p.19-25

2002

Volltextzugriff (PDF)

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models

Annals of oncology, 2010-07, Vol.21 (7), p.1472-1481

2010

Volltextzugriff (PDF)

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group

European journal of cancer (1990), 2006-11, Vol.42 (17), p.2991-2995

2006

Volltextzugriff (PDF)

Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy

Anti-cancer drugs, 2004-10, Vol.15 (9), p.843-847

2004

Volltextzugriff (PDF)

Influence of pegylated interferon-α therapy on plasma levels of citrulline and arginine in melanoma patients

Amino acids, 2007, Vol.32 (1), p.121-126

2007

Volltextzugriff (PDF)

Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma

Journal of interferon & cytokine research, 2008-05, Vol.28 (5), p.283-286

2008

Volltextzugriff (PDF)

Phase I Study of Subcutaneously Administered Recombinant Human Interleukin 12 in Patients with Advanced Renal Cell Cancer

Clinical cancer research, 1999-12, Vol.5 (12), p.3983-3989

1999

Volltextzugriff (PDF)

Interferon-α induced Raynaud's syndrome

Annals of oncology, 2000-11, Vol.11 (11), p.1501-1502

2000

Volltextzugriff (PDF)

Immunochemotherapy with interleukin-2, interferon-α and 5-fluorouracil for progressive metastatic renal cell carcinoma : a multicenter phase II study

British journal of cancer, 2000-02, Vol.82 (4), p.772-776

2000

Volltextzugriff (PDF)

Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma

Journal of neurology, neurosurgery and psychiatry, 2003-04, Vol.74 (4), p.507-509

2003

Volltextzugriff (PDF)

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

The Lancet (British edition), 2005-10, Vol.366 (9492), p.1189-1196

2005

Volltextzugriff (PDF)

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin

European journal of cancer (1990), 2002, Vol.38 (11), p.1501-1511

2002

Volltextzugriff (PDF)

A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix

British Journal of Cancer, 1999-07, Vol.80 (9), p.1387-1391

1999

Volltextzugriff (PDF)

Regulation of ferritin: a specific role for interferon-alpha (IFN-α)? The acute phase response in patients treated with IFN-α-2b

European journal of clinical investigation, 2002-03, Vol.32 (s1), p.79-83

2002

Volltextzugriff (PDF)

Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6747-6755

2005

Volltextzugriff (PDF)

Intrapleural administration of tumour necrosis factor-alpha (TNFα) in patients with mesothelioma: cytokine patterns and acute-phase protein response

European journal of clinical investigation, 2000-04, Vol.30 (4), p.336-343

2000

Volltextzugriff (PDF)

1 – 25 von 342

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(285)
Mit Volltextzugriff
(290)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(215)
Life Sciences & Biomedicine
(116)
Humans
(98)
Physical Sciences
(95)
Technology
(72)
Physics
(69)
Female
(64)
Male
(63)
Middle Aged
(60)
Science & Technology - Other Topics
(55)
Physics, Applied
(52)
Aged
(50)
Engineering
(49)
Nanoscience & Nanotechnology
(49)
Adult
(48)
Biological And Medical Sciences
(47)
Engineering, Electrical & Electronic
(46)
Medical Sciences
(44)
Oncology
(42)
Pharmacology. Drug Treatments
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors

Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma

A medical cause for fifty shades of grey

258 Macrocytosis as a potential parameter associated with outcome in the treatment with tyrosine kinase inhibitors

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: A corollary study to EORTC trial 18952

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group

Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy

Influence of pegylated interferon-α therapy on plasma levels of citrulline and arginine in melanoma patients

Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma

Phase I Study of Subcutaneously Administered Recombinant Human Interleukin 12 in Patients with Advanced Renal Cell Cancer

Interferon-α induced Raynaud's syndrome

Immunochemotherapy with interleukin-2, interferon-α and 5-fluorouracil for progressive metastatic renal cell carcinoma : a multicenter phase II study

Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin

A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix

Regulation of ferritin: a specific role for interferon-alpha (IFN-α)? The acute phase response in patients treated with IFN-α-2b

Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

Intrapleural administration of tumour necrosis factor-alpha (TNFα) in patients with mesothelioma: cytokine patterns and acute-phase protein response

Suchergebnisse filtern